Roper Technologies, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Amounts are in millions, except per-share data. Roper is a diversified technology company focused on vertical software and technology-enabled products. TransCore, Zetec, CIVCO Radiotherapy and the majority stake in Indicor are reported as discontinued operations.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $1,531.2 | $1,310.8 | $3,000.9 | $2,590.6 |
| Gross margin | 69.7% | 69.5% | 69.5% | 69.8% |
| Operating income | $435.3 | $362.9 | $836.3 | $718.8 |
| Net earnings from continuing operations | $361.0 | $225.0 | $645.3 | $461.4 |
| Diluted continuing-operations EPS | $3.36 | $2.11 | $6.02 | $4.32 |
| Operating cash flow from continuing operations | Not separately provided | Not separately provided | $785.0 | $331.0 |
- Q2 revenue increased 16.8%; organic growth was 9.1%, with acquisitions contributing 7.9% and foreign exchange reducing growth by 0.2%. For the first half, revenue rose 15.8%, including 8.5% organic growth.
- Q2 segment revenue growth: Application Software 22.8% (6.4% organic), Network Software 4.4% (4.8% organic), and Technology Enabled Products 18.3% (18.6% organic). Application Software growth included a substantial acquisition contribution.
- Q2 operating margin was 28.4%, up from 27.7%. Segment operating margins were 26.1% for Application Software, 42.8% for Network Software and 34.5% for Technology Enabled Products. Segment operating profit excludes corporate and enterprise-wide stock compensation expenses.
- Q2 net earnings included $3.9 of net discontinued-operations income, including a $3.9 disposition gain. First-half 2022 earnings were unusually elevated by large divestiture gains; reported total net earnings were $2,289.3 versus $648.0 in first-half 2023, so continuing-operations comparisons are more informative.
Cash, debt and liquidity
- At June 30, 2023, cash and equivalents were $1,462.8, total debt net of deferred financing costs was $6,666.1, and net debt was $5,203.3. Net debt to total net capital was 23.7%, down from 26.8% at December 31, 2022.
- Cash increased by $670.0 during the first half. Continuing-operations operating cash flow was $785.0; continuing investing activities used $52.3 and financing activities used $75.8. Prior-year cash flow was affected by cash taxes paid on divestitures and divestiture proceeds.
- No borrowings were outstanding under the $3.5 billion unsecured credit facility; letters of credit were $18.4. The company reported compliance with debt covenants and expects cash, operating cash generation and facility availability to fund foreseeable operating needs.
- Current debt included $699.8, with a $700 million senior note maturity in 2023. Net working capital, excluding cash and current debt, was negative $920.8; the filing attributes changes partly to deferred-revenue timing and Frontline renewal cycles.
Changes, outlook and key risks
- Q2 net interest expense fell to $34.8 from $44.7, attributed to higher interest income on cash and lower weighted-average debt balances. The effective tax rate was 22.1%, compared with 29.0%, with the prior-year rate affected by tax expense related to the Indicor transaction.
- Equity investment activity was a $66.0 gain in Q2, primarily reflecting the fair-value change in Roper’s 48.1% Indicor interest and dividend distributions. The investment is Level 3 and its valuation depends on significant management judgments; the valuation method changed during Q2.
- Remaining performance obligations were $4,201.3; $2,746.8, about 65%, was expected to be recognized over the next 12 months. Backlog grew 11% year over year, with 8% organic growth and 3% from acquisitions.
- Roper acquired Promium for $16.5 in May. It also agreed to acquire Replicon for approximately $450, including an estimated $80 cash tax benefit; closing was expected in Q3 2023. Management gave no specific earnings or revenue guidance in the supplied filing text.
- Management expects positive operating cash flow and debt reduction, but the pace depends on acquisitions, business performance and economic and market conditions. Risks cited include inflation, supply-chain and labor constraints, interest rates, geopolitical events, cybersecurity and data privacy, litigation, competition, and potential goodwill or intangible-asset impairments. No interim impairment review was considered necessary in 2023.
- The $45.0 Verathon patent-litigation settlement was paid in Q1 2023. Management said ordinary-course legal matters were adequately provided for and not expected to materially affect results, while noting no assurance can be given.
Important facts for investors to verify
- How much reported Application Software growth and future earnings depend on acquisitions, and whether organic growth remains broad-based.
- The assumptions and sensitivity behind the Level 3 Indicor valuation, including the Q2 methodology change and future distributions.
- The timing and funding of the 2023 note maturity and Replicon acquisition, and the effect on net debt and interest costs.
- Whether backlog converts to revenue as expected, particularly given SaaS renewal timing and the concentration of Frontline renewals in Q3.
- Potential effects of inflation, labor and supply constraints, cybersecurity and AI-related risks, litigation, and other economic uncertainties.